Meropan

Fluoxetine, the active ingredient in Meropan, is a selective serotonin reuptake inhibitor (SSRI) presented as an oral dosage form for oral use. It is prescribed for the treatment of major depressive disorder and several anxiety‑related conditions in adult patients. The medication works by increasing serotonin levels in the brain, which can improve mood, reduce compulsive thoughts, and alleviate panic symptoms.

GNH USA supplies Meropan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Fluoxetine is an SSRI indicated for several psychiatric disorders. - Major depressive disorder: alleviates depressive symptoms and improves overall mood. - Obsessive‑compulsive disorder: reduces intrusive thoughts and compulsive behaviors. - Panic disorder: decreases the frequency and intensity of panic attacks. - Bulimia nervosa: helps reduce binge‑eating episodes and associated anxiety. - Premenstrual dysphoric disorder: eases mood swings and irritability during the luteal phase.

Fluoxetine may cause a range of adverse reactions.

Common Side Effects: - Nausea - Headache - Insomnia - Dry mouth - Dizziness - Decreased libido

Serious or Rare Side Effects: - Serotonin syndrome (potentially life‑threatening) - Suicidal thoughts or behavior, especially in young adults - Severe allergic reaction (anaphylaxis) - QT interval prolongation on ECG - Hyponatremia (low blood sodium)

Before initiating therapy, consider the following precautions. - Psychiatric history: monitor for worsening depression or emergent suicidal ideation. - Hepatic function: assess liver status and adjust if severe impairment is present. - Concomitant serotonergic agents: evaluate risk of serotonin syndrome. - Elderly patients: increased susceptibility to hyponatremia and falls. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Fluoxetine interacts with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin syndrome. - Thioridazine or pimozide: can cause cardiac arrhythmias. - Linezolid or tramadol: heightened serotonergic activity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) or anticoagulants: increased bleeding risk. - Carbamazepine: may reduce fluoxetine plasma levels. - Alcohol: can exacerbate CNS depression and impair judgment.